MCID: GLL017
MIFTS: 43

Gallbladder Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gallbladder Adenocarcinoma

MalaCards integrated aliases for Gallbladder Adenocarcinoma:

Name: Gallbladder Adenocarcinoma 12 14 69
Adenocarcinoma of the Gallbladder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3500
NCIt 47 C9166
UMLS 69 C0279651

Summaries for Gallbladder Adenocarcinoma

Disease Ontology : 12 A gallbladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gallbladder Adenocarcinoma, also known as adenocarcinoma of the gallbladder, is related to adenocarcinoma of the gallbladder and extrahepatic biliary tract and gallbladder pleomorphic giant cell adenocarcinoma, and has symptoms including abdominal pain An important gene associated with Gallbladder Adenocarcinoma is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and ErbB signaling pathway. The drugs Capecitabine and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include liver, breast and pancreas, and related phenotypes are Decreased viability with paclitaxel and cellular

Related Diseases for Gallbladder Adenocarcinoma

Diseases related to Gallbladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 64)
id Related Disease Score Top Affiliating Genes
1 adenocarcinoma of the gallbladder and extrahepatic biliary tract 12.1
2 gallbladder pleomorphic giant cell adenocarcinoma 11.0
3 infiltrating ureter transitional cell carcinoma 10.7 EGFR ERBB2
4 skin sarcoma 10.7 EGFR ERBB2
5 her2-receptor negative breast cancer 10.6 EGFR ERBB2
6 subglottis verrucous carcinoma 10.6 EGFR ERBB2
7 gastric tubular adenocarcinoma 10.6 EGFR ERBB2
8 penis squamous cell carcinoma 10.6 EGFR ERBB2
9 breast fibrosarcoma 10.6 EGFR ERBB2
10 tubular adenocarcinoma 10.6 EGFR MUC2
11 dmd-related dilated cardiomyopathy 10.6 EGFR ERBB2
12 cutaneous lupus erythematosus 10.6 ERBB2 MYB
13 adenocarcinoma 10.6
14 occupational dermatitis 10.6 EGFR ERBB2
15 malignant thyroid stimulating hormone producing neoplasm of pituitary gland 10.5 EGFR ERBB2
16 comedo carcinoma 10.5 EGFR ERBB2
17 gorham's disease 10.5 EGFR ERBB2
18 distal monosomy 7q36 10.5 EGFR ERBB2
19 anal paget's disease 10.4 EGFR ERBB2
20 hip subluxation 10.4 EGFR ERBB2 MUC2
21 sohval soffer syndrome 10.4 EGFR ERBB2 MUC2
22 kidney benign neoplasm 10.4 ERBB2 MUC2
23 ureter adenocarcinoma 10.4 EGFR ERBB2 MUC2
24 nominal aphasia 10.4 EGFR ERBB2 MUC2
25 gallbladder cancer 10.3 EGFR ERBB2 MUC2
26 brown-vialetto-van laere syndrome 10.3 EGFR ERBB2 MUC2
27 gastric cancer, somatic 10.3 EGFR ERBB2 MUC2
28 rectum kaposi's sarcoma 10.3 EGFR ERBB2
29 cecum adenocarcinoma 10.2 EGFR MUC2
30 paroxysmal nocturnal hemoglobinuria 10.2 EGFR ERBB2 SRC
31 uterine corpus apoplectic leiomyoma 10.2 EZH2 MUC2
32 kidney clear cell sarcoma 10.2 EGFR ERBB2 EZH2
33 lacrimal gland mucoepidermoid carcinoma 10.2 EGFR ERBB2
34 acinar cell cystadenocarcinoma 10.2 MUC2 PSCA
35 pancreatic signet ring cell adenocarcinoma 10.1 MUC2 SRC
36 cervical cancer, somatic 10.1 EGFR ERBB2 EZH2
37 bardet-biedl syndrome 10.1 EGFR ERBB2 PSCA
38 dysembryoplastic neuroepithelial tumor 10.0 EGFR ERBB2 PSCA
39 ductal carcinoma in situ 10.0 EGFR ERBB2
40 esophagus lymphoma 10.0 EGFR ERBB2 PSCA
41 cholecystitis 9.9
42 xanthogranulomatous cholecystitis 9.8
43 acute porphyria 9.8 EGFR ERBB2 MUC2 PSCA
44 gastrointestinal stromal tumor 9.6
45 pulmonary hypertension 9.6
46 chronic lymphocytic leukemia 9.6
47 leukemia 9.6
48 ulcerative colitis 9.6
49 gallbladder adenoma 9.6
50 colitis 9.6

Graphical network of the top 20 diseases related to Gallbladder Adenocarcinoma:



Diseases related to Gallbladder Adenocarcinoma

Symptoms & Phenotypes for Gallbladder Adenocarcinoma

UMLS symptoms related to Gallbladder Adenocarcinoma:


abdominal pain

GenomeRNAi Phenotypes related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR ERBB2 SRC
2 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Gallbladder Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.97 EGFR ERBB2 EZH2 MUC2 MYB S1PR1
2 embryo MP:0005380 9.87 MYB S1PR1 SRC TSG101 EGFR ERBB2
3 endocrine/exocrine gland MP:0005379 9.8 EGFR ERBB2 EZH2 MUC2 MYB SRC
4 integument MP:0010771 9.63 EZH2 MYB SRC TSG101 EGFR ERBB2
5 neoplasm MP:0002006 9.5 EGFR ERBB2 EZH2 MUC2 PSCA SRC
6 normal MP:0002873 9.17 EGFR ERBB2 EZH2 MYB PSCA S1PR1

Drugs & Therapeutics for Gallbladder Adenocarcinoma

Drugs for Gallbladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
2
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
3
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5 Antimetabolites Phase 3,Phase 2,Phase 1
6 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
7 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
8 Liver Extracts Phase 3,Phase 2,Phase 1
9 Anti-Infective Agents Phase 3,Phase 2,Phase 1
10 Antiviral Agents Phase 3,Phase 2,Phase 1
11
Bevacizumab Approved, Investigational Phase 2 216974-75-3
12
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
13
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
14
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
15
Trastuzumab Approved, Investigational Phase 2,Phase 1 180288-69-1 9903
16
Melphalan Approved Phase 2 148-82-3 4053 460612
17
Pancrelipase Approved Phase 2,Phase 1 53608-75-6
18
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
19
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
20
Levoleucovorin Approved Phase 2,Phase 1 68538-85-2
21
Trioxsalen Approved Phase 2 3902-71-4 5585
22
Trametinib Approved Phase 2 871700-17-3 11707110
23
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
24
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
25
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
26
Everolimus Approved Phase 2 159351-69-6 6442177
27
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
28
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
29
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
30
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
31
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
32
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
33
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
34
leucovorin Approved, Nutraceutical Phase 1, Phase 2 58-05-9 143 6006
35 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
36
Docetaxel Approved May 1996, Investigational Phase 2,Phase 1 114977-28-5 148124 9877265
37 Dolastatin 10 Investigational Phase 2 110417-88-4
38
Camptothecin Experimental Phase 1, Phase 2 7689-03-4
39
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
40
Cediranib Investigational Phase 2 288383-20-0 9933475
41
Maleic acid Experimental Phase 2 110-16-7 444266
42 Angiogenesis Inhibitors Phase 2,Phase 1
43 Angiogenesis Modulating Agents Phase 2,Phase 1
44
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
45 Micronutrients Phase 2,Phase 1
46 Nicotinic Acids Phase 2
47 Protein Kinase Inhibitors Phase 2,Phase 1
48 Trace Elements Phase 2,Phase 1
49 Vitamin B Complex Phase 2,Phase 1
50 Vitamins Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 65)

id Name Status NCT ID Phase Drugs
1 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
2 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
3 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Recruiting NCT02798510 Phase 3 capecitabine;gemcitabine
4 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
5 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
6 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Unknown status NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
7 A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
8 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2 Bevacizumab;Gemcitabine;Oxaliplatin
9 A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts Completed NCT01007552 Phase 2 Gemcitabine, Capecitabine and Bevacizumab
10 A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC Completed NCT01267344 Phase 2 gemcitabine, oxaliplatin;cetuximab, gemcitabine, oxaliplatin
11 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
12 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
13 S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
14 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
15 Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer Completed NCT00073905 Phase 2 capecitabine plus gemcitabine
16 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
17 Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer Completed NCT00075504 Phase 2 triapine;gemcitabine
18 Avastin and Tarceva for Upper Gastrointestinal Cancers Completed NCT00350753 Phase 2 Erlotinib and bevacizumab
19 Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma Completed NCT01389414 Phase 2 Panitumumab plus GEMOX chemotherapy;GEMOX chemotherapy
20 Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer Completed NCT00660140 Phase 2 Gemcitabine;Carboplatin
21 Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
22 Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
23 Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride
24 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma Completed NCT00338988 Phase 2 Capecitabine;Oxaliplatin
25 A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers Completed NCT00660699 Phase 2 Gemcitabine;Docetaxel
26 Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Completed NCT00003557 Phase 2 dolastatin 10
27 Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas Completed NCT00003923 Phase 2 porfimer sodium
28 Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct Completed NCT01153750 Phase 2 Glivec
29 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
30 Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Completed NCT00033462 Phase 2 erlotinib hydrochloride
31 Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer Recruiting NCT02333188 Phase 1, Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
32 Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma Recruiting NCT02836847 Phase 2 GEMOX;Cetuximab;Trastuzumab;Gefitinib;Lapatinib;Everolimus;Sorafenib;Crizotinib
33 Pilot Study of Percutaneous Irreversible Electroporation to Treat Unresectable Hepatic Carcinoma Close to the Gallbladder Recruiting NCT02332551 Phase 1, Phase 2
34 Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer Recruiting NCT01855724 Phase 2 Gemcitabine-Pazopanib
35 A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy Active, not recruiting NCT02053376 Phase 2 Regorafenib
36 S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct Active, not recruiting NCT00789958 Phase 2 capecitabine;gemcitabine hydrochloride
37 Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies Not yet recruiting NCT03043547 Phase 2 nal-IRI;5-FU;leucovorin
38 Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Terminated NCT00085410 Phase 2 bortezomib
39 Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract Terminated NCT00012246 Phase 2
40 Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers Terminated NCT00832637 Phase 2 Cisplatin;Erlotinib;Gemcitabine
41 Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers Terminated NCT01229111 Phase 2 cediranib maleate;oxaliplatin;leucovorin calcium;fluorouracil
42 BMS-247550 in Treating Patients With Liver or Gallbladder Cancer Terminated NCT00023946 Phase 2 ixabepilone
43 Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery Withdrawn NCT01859182 Phase 2 selumetinib;Akt inhibitor MK2206
44 Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Completed NCT00028496 Phase 1
45 Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer Completed NCT00266097 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin;gemcitabine hydrochloride;Oxaliplatin
46 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
47 Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer Completed NCT00544193 Phase 1 gemcitabine hydrochloride
48 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
49 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
50 Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer Completed NCT00027534 Phase 1

Search NIH Clinical Center for Gallbladder Adenocarcinoma

Genetic Tests for Gallbladder Adenocarcinoma

Anatomical Context for Gallbladder Adenocarcinoma

MalaCards organs/tissues related to Gallbladder Adenocarcinoma:

39
Liver, Breast, Pancreas, Lung, Bone, Small Intestine, Colon

Publications for Gallbladder Adenocarcinoma

Articles related to Gallbladder Adenocarcinoma:

(show top 50) (show all 89)
id Title Authors Year
1
Gallbladder Adenocarcinoma as the First Manifestation of Germline BRCA1 Mutation. ( 28785956 )
2017
2
Metastasis of gallbladder adenocarcinoma to the skin of the external auditory canal, a case report. ( 28522135 )
2017
3
Spontaneous cholecystocutaneous fistula as a primary manifestation of gallbladder adenocarcinoma associated with gallbladder lithiasis - case report. ( 28730246 )
2017
4
Decision of surgical approach for advanced gallbladder adenocarcinoma based on a Bayesian network. ( 28876457 )
2017
5
Cytokeratin 17 Expression is Associated With Poor Prognosis in Gallbladder Adenocarcinoma. ( 26990743 )
2016
6
Diffusion-weighted magnetic resonance imaging of gallbladder adenocarcinoma: analysis with emphasis on histologic grade. ( 27133665 )
2016
7
Immunohistochemical expression of mucin antigens in gallbladder adenocarcinoma: MUC1-positive and MUC2-negative expression Is associated with vessel invasion and shortened survival. ( 27672051 )
2016
8
Gallbladder adenocarcinoma and paraneoplastic parathyroid hormone mediated hypercalcemia. ( 27081650 )
2016
9
Breast metastasis from recurrent gallbladder adenocarcinoma: a case report with review of the literature. ( 27512606 )
2016
10
Gallbladder neuroendocrine carcinoma: report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma. ( 26339390 )
2015
11
18F-FDG PET/CT Imaging of Gallbladder Adenocarcinoma - A Pictorial Review. ( 26430572 )
2015
12
Dermatomyositis as the first manifestation of gallbladder adenocarcinoma: case report and literature overview. ( 25890241 )
2015
13
BRMS1 and HPA as Progression, Clinical Biological Behaviors, and Poor Prognosis-related Biomarkers for Gallbladder Adenocarcinoma. ( 26200836 )
2015
14
Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naA^ve pT2 gallbladder adenocarcinoma patients. ( 26266900 )
2015
15
Surgical resection of solid gallbladder adenocarcinoma presenting as a large mass: report of a case. ( 25884804 )
2015
16
Vitamin D receptor genetic variants are associated with susceptibility of gallbladder adenocarcinoma in a Chinese cohort. ( 25078595 )
2014
17
Gallbladder adenocarcinoma with sarcoid-like reaction in regional lymph nodes: report of a case. ( 25495692 )
2014
18
Lymph node status after resection for gallbladder adenocarcinoma: Prognostic implications of different nodal staging/scoring systems. ( 25312786 )
2014
19
Overexpression of MTA1 and loss of KAI-1 and KiSS-1 expressions are associated with invasion, metastasis, and poor-prognosis of gallbladder adenocarcinoma. ( 25688501 )
2014
20
Histological phenotype is correlated with the wall-invasion pattern of gallbladder adenocarcinoma. ( 25355436 )
2014
21
Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma. ( 26176038 )
2014
22
Re: metastasis of gallbladder adenocarcinoma to Bauhin's valve: an extremely rare cause of intestinal obstruction. ( 25246829 )
2014
23
Cheek metastasis from gallbladder adenocarcinoma. ( 23669176 )
2013
24
Secondary Sclerosing Cholangitis due to Gallbladder Adenocarcinoma. ( 23626514 )
2013
25
MTDH and EphA7 are markers for metastasis and poor prognosis of gallbladder adenocarcinoma. ( 21964981 )
2013
26
Gastrointestinal Stromal Tumor with Synchronous Gallbladder Adenocarcinoma. ( 23749654 )
2013
27
Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance. ( 23475628 )
2013
28
Expression of Cell Cycle-Related Proteins, p16, p53 and p63 as Important Prognostic Markers in Gallbladder Adenocarcinoma. ( 24178677 )
2013
29
Antiproliferative and apoptosis-inducing activity of curcumin against human gallbladder adenocarcinoma cells. ( 23645731 )
2013
30
Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma. ( 23544944 )
2013
31
PSCA and Oct-4 expression in the benign and malignant lesions of gallbladder: implication for carcinogenesis, progression, and prognosis of gallbladder adenocarcinoma. ( 23984394 )
2013
32
Clinicopathological features and CCT2 and PDIA2 expression in gallbladder squamous/adenosquamous carcinoma and gallbladder adenocarcinoma. ( 23782473 )
2013
33
Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: A propensity score-matched Surveillance, Epidemiology, and End Results analysis. ( 23876364 )
2013
34
Correlation of S1P1 and ERp29 expression to progression, metastasis, and poor prognosis of gallbladder adenocarcinoma. ( 23558074 )
2013
35
Coexistence of xanthogranulomatous cholecystitis and gallbladder adenocarcinoma: a fortuitous association? ( 24471194 )
2013
36
Cutaneous metastasis of gallbladder adenocarcinoma in a patient with chronic lymphocytic leukemia: a case report and review of the literature. ( 23467457 )
2013
37
Expression of MUC1 and MUC4 in gallbladder adenocarcinoma. ( 23136569 )
2012
38
Up-regulation of galectin-3 and Sambucus nigra agglutinin binding site is associated with invasion, metastasis and poor-progression of the gallbladder adenocarcinoma. ( 22497866 )
2012
39
Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma. ( 22076922 )
2012
40
Gallbladder adenocarcinoma: evaluation of the prognostic factors in 100 resectable cases in Brazil. ( 22569972 )
2012
41
Metastatic gallbladder adenocarcinoma with signet-ring cells: A case report. ( 21917161 )
2011
42
Giant gallbladder: adenocarcinoma complicated with empyema. ( 21217498 )
2011
43
Ala499Val (C>T) and Lys939Gln (A>C) polymorphisms of the XPC gene: their correlation with the risk of primary gallbladder adenocarcinoma--a case-control study in China. ( 21113018 )
2011
44
Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. ( 21455631 )
2011
45
Frequency of genetic alterations observed in cell cycle regulatory proteins and microsatellite instability in gallbladder adenocarcinoma: a translational perspective. ( 21545232 )
2011
46
Gallbladder adenocarcinoma with extended intramural spread in adenomyomatosis of the gallbladder with the pearl necklace sign. ( 21375832 )
2011
47
Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. ( 21719208 )
2011
48
Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. ( 21307665 )
2011
49
Identification of musashi-1 and ALDH1 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. ( 22012766 )
2010
50
Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma. ( 19904536 )
2010

Variations for Gallbladder Adenocarcinoma

Expression for Gallbladder Adenocarcinoma

Search GEO for disease gene expression data for Gallbladder Adenocarcinoma.

Pathways for Gallbladder Adenocarcinoma

Pathways related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13 EGFR EPHA7 ERBB2 S1PR1 SRC
2
Show member pathways
12.1 EGFR ERBB2 SRC
3 12.07 EGFR ERBB2 SRC
4
Show member pathways
12.06 EGFR ERBB2 SRC
5 11.93 EGFR ERBB2 SRC
6
Show member pathways
11.88 EGFR ERBB2 SRC
7
Show member pathways
11.85 EGFR ERBB2 SRC
8
Show member pathways
11.73 EGFR ERBB2 SRC
9 11.44 EGFR ERBB2 SRC
10 11.4 EGFR ERBB2 SRC
11 11.33 EGFR ERBB2 SRC
12
Show member pathways
11.3 EGFR ERBB2 SRC
13 11.18 EGFR ERBB2 SRC
14 11.13 EGFR SRC
15 11.08 EGFR EPHA7 ERBB2 SRC
16 11.07 EGFR ERBB2
17 11.04 EGFR ERBB2
18 10.99 EGFR ERBB2 SRC
19 10.95 EGFR SRC
20 10.77 EGFR SRC
21 10.71 EGFR SRC
22 10.66 EGFR SRC TSG101

GO Terms for Gallbladder Adenocarcinoma

Cellular components related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endosome membrane GO:0010008 8.8 EGFR ERBB2 TSG101

Biological processes related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of GTPase activity GO:0043547 9.88 EGFR ERBB2 EZH2 S1PR1
2 negative regulation of transcription, DNA-templated GO:0045892 9.83 EZH2 MYB SRC TSG101
3 protein autophosphorylation GO:0046777 9.69 EGFR ERBB2 SRC
4 positive regulation of protein phosphorylation GO:0001934 9.67 EGFR EPHA7 ERBB2
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.63 EGFR EPHA7 ERBB2
6 liver regeneration GO:0097421 9.57 EGFR EZH2
7 cellular response to reactive oxygen species GO:0034614 9.56 EGFR SRC
8 peptidyl-tyrosine phosphorylation GO:0018108 9.56 EGFR EPHA7 ERBB2 SRC
9 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 9.55 EGFR TSG101
10 regulation of cell motility GO:2000145 9.54 EGFR ERBB2
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.5 EGFR MYB S1PR1
12 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.48 EGFR EPHA7
13 negative regulation of ERBB signaling pathway GO:1901185 9.43 EGFR ERBB2
14 regulation of cell-cell adhesion GO:0022407 9.4 EPHA7 SRC
15 regulation of bone resorption GO:0045124 9.37 S1PR1 SRC
16 ERBB2 signaling pathway GO:0038128 9.33 EGFR ERBB2 SRC
17 regulation of ERK1 and ERK2 cascade GO:0070372 9.13 EGFR EPHA7 ERBB2
18 positive regulation of MAP kinase activity GO:0043406 8.92 EGFR ERBB2 EZH2 SRC

Molecular functions related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.62 EGFR EPHA7 ERBB2 SRC
2 ubiquitin protein ligase binding GO:0031625 9.56 CCT2 EGFR SRC TSG101
3 ephrin receptor binding GO:0046875 9.37 EPHA7 SRC
4 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.16 EGFR ERBB2
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR EPHA7 ERBB2
6 protein tyrosine kinase activity GO:0004713 8.92 EGFR EPHA7 ERBB2 SRC

Sources for Gallbladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....